查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018600

GLP-1受體促效劑市場：2026-2032年全球市場預測（依藥物類別、劑型、給藥途徑、應用及分銷管道分類）

GLP-1 Receptor Agonist Market by Drug Class, Drug Type, Route of Administration, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，GLP-1 受體促效劑市場價值將達到 455.9 億美元，到 2026 年將成長至 515.7 億美元，至 2032 年將達到 1,126.2 億美元，年複合成長率為 13.78%。

主要市場統計數據
基準年 2025 455.9億美元
預計年份：2026年 515.7億美元
預測年份 2032 1126.2億美元
複合年成長率 (%) 13.78%

簡潔且全面的概述，將 GLP-1 受體促效劑定位為變革性藥物，重塑治療策略和相關人員的決策。

GLP-1受體促效劑的出現和發展徹底改變了代謝性疾病和心血管疾病的治療方法，推動了藥物研發、製劑和給藥方式的快速創新。這些藥物具有類似腸促胰島素的作用機制，其臨床應用範圍已從血糖控制擴展到更廣泛的終點，例如體重管理和心血管風險調控。因此，臨床、保險和商業領域的相關人員面臨著更複雜的決策環境，治療價值、病患可近性和長期療效等因素相互交織。

對 GLP-1 療法中產品開發、患者照護路徑和商業策略的關鍵結構和臨床變化進行詳細檢驗。

目前，GLP-1受體促效劑正經歷幾項變革性的變化，這些變化對產業領導者和臨床醫生都具有重要意義。首先，其治療適應症已擴展。這些藥物現在不僅用於血糖控制，還用於減肥和降低心臟代謝風險，這正在改變臨床路徑和處方考慮。同時，藥物科學的進步日新月異，使得長效製劑和短效製劑之間的差異更加清晰，從而催生了新的給藥模式，進而影響患者的用藥依從性和偏好。

分析美國在 2025 年實施的關稅措施將如何影響 GLP-1 療法供應鏈的複雜性、採購決策和業務永續營運。

美國2025年實施的關稅政策和貿易措施將大幅增加GLP-1供應鏈的複雜性，影響採購決策、成本結構和策略規劃。儘管活性成分和某些製劑原料在全球範圍內流通，但關稅增加了原料的獲取成本，可能促使企業調整採購策略，並將生產轉移到關稅更優惠的地區。為此，各公司正在重新評估供應商所在地，探索擴大近岸生產，並加速達成雙邊供應協議，以降低進口關稅和物流波動帶來的風險。

基於關鍵細分的洞察揭示了藥物類別、製劑類型、給藥途徑、治療用途和分銷管道如何決定策略重點。

細分市場洞察揭示了不同藥物類別、藥物類型、給藥途徑、臨床用途和通路之間的差異，從而影響產品定位和生命週期優先順序。在藥物類別內部，Dulaglutide、Liraglutide和Semaglutide等已上市藥物各自展現出獨特的臨床特徵和依證，這會影響指南納入、處方醫生的偏好，並最終促效劑通訊和醫學事務策略。在藥物類型層面，長效和短效促效劑之間的差異體現在用藥依從性模式、給藥便利性以及產品組合權衡等方面，促使企業調整其製劑研發投入，以適應目標患者群體和醫療環境。

整合對美洲、歐洲、中東和非洲以及亞太地區的監管、支付方和基礎設施差異的區域洞察，以塑造採用軌跡。

GLP-1受體促效劑的區域趨勢受美洲、歐洲、中東和非洲以及亞太地區法規環境、支付方結構和醫療服務模式的影響，每個地區都有其獨特的應用路徑和營運考量。在美洲，由於心血管代謝疾病領域強力的臨床倡導以及指南的快速納入，GLP-1受體激動劑的應用得到了加速；然而，報銷框架和支付方政策的多樣性使得有針對性的價值論證和療效數據變得至關重要，以確保廣泛的可及性。因此，商業策略強調真實世界數據（REW）和與支付方的合作，以將臨床效益與醫療覆蓋的治療聯繫起來。

從競爭定位、策略聯盟以及生產和監管重點等方面的綜合觀點，決定 GLP-1 製劑領域公司層面的成功。

GLP-1領域的競爭格局和企業發展趨勢反映了以下幾個面向：成熟的製藥企業領導地位、有針對性的生命週期最佳化，以及專注於產能和給藥方法創新的服務供應商生態系統的不斷擴展。主要企業保持強大的臨床試驗計畫和豐富的監管合規經驗，同時積極推行包括拓展適應症、差異化給藥方法以及投資口服和替代給藥平台在內的策略。這些努力得到了大規模研發體系和全球監管合規框架的支持，從而能夠產生先進的證據並影響相關指南的製定。

為行業領導者提供可操作的建議，重點關注證據協調、價值鏈韌性、管道特定商業化和基於結果的契約，以保護管道價值。

隨著GLP-1療法的日益普及，產業領導者應採取一系列切實可行的措施，以應對商業化過程中的複雜挑戰，並確保其研發管線的價值。首先，臨床開發和證據生成必須儘早與支付方和指南的要求保持一致，優先考慮對支付方、臨床醫生和患者都至關重要的療效指標。這種一致性將縮短醫保報銷決策的時間，並在證實其具有超越替代終點的顯著真實世界獲益後，促進更廣泛的應用。

採用透明嚴謹的調查方法，結合與關鍵相關人員的訪談、監管和臨床文獻分析以及情境檢驗，以獲得可操作的見解。

本執行報告的調查方法融合了多種定性和定量方法，以確保獲得全面而深入的洞察。主要研究包括對臨床醫生、支付方、採購專業人員和商業部門領導者進行結構化訪談，以了解臨床導入、報銷談判和分銷執行中的決策因素。除與這些相關人員進行討論外，還對監管指南、臨床試驗註冊數據和同行評審文獻進行了系統性回顧，以確定特定適應症的證據要求和安全性概況。

一項權威的綜合分析強調，需要在開發、供應和商業化的所有階段採取以證據主導的綜合策略，才能實現治療藥物的潛力。

總之，GLP-1受體促效劑代表著一類快速發展的治療藥物，其應用範圍已超越傳統的血糖控制，擴展至更廣泛的心血管代謝疾病治療，從而推動了新的臨床模式和商業性需求。在製劑創新、競爭格局和不斷變化的支付方期望的交織下，臨床開發、監管合作、供應鏈策略以及跨銷售管道商業化都需要採取整合策略。積極主動地將循證醫學證據與支付方需求相結合、預見貿易政策變化而實現供應鏈多元化、並投資於患者支持和療效追蹤的利益相關人員，將更有能力將臨床潛力轉化為永續的治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：GLP-1受體促效劑市場：依藥物類別分類

  • Dulaglutide
  • Liraglutide
  • Semaglutide

第9章：GLP-1受體促效劑市場（依藥物類型分類）

  • 長效促效劑
  • 短效促效劑

第10章：GLP-1受體促效劑市場：依給藥途徑分類

  • 口服
  • 腸外

第11章：GLP-1受體促效劑市場：依應用領域分類

  • 心血管健康
  • 糖尿病管理
  • 體重管理

第12章：GLP-1受體促效劑市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：GLP-1受體促效劑市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：GLP-1受體促效劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：GLP-1受體促效劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國GLP-1受體促效劑市場

第17章：中國GLP-1受體促效劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • AstraZeneca Inc.
  • Bachem Group
  • Biopharma PEG
  • Boehringer Ingelheim International GmbH
  • Calibrate Health, Inc.
  • Cleveland Clinic
  • Daiichi Sankyo Company, Limited
  • Diabetes UK
  • Eli Lilly and Company
  • GenScript
  • GlaxoSmithKline plc
  • GoodRx, Inc.
  • Hanmi Pharm.Co.,Ltd.
  • Innovent Biologics, Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Patsnap（UK）Ltd.
  • Pfizer Inc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Twist Bioscience Corporation
  • WebMD LLC.
Product Code: MRR-B9334AD6C5EF

The GLP-1 Receptor Agonist Market was valued at USD 45.59 billion in 2025 and is projected to grow to USD 51.57 billion in 2026, with a CAGR of 13.78%, reaching USD 112.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 45.59 billion
Estimated Year [2026] USD 51.57 billion
Forecast Year [2032] USD 112.62 billion
CAGR (%) 13.78%

A concise but comprehensive introduction framing GLP-1 receptor agonists as transformative agents reshaping therapeutic strategy and stakeholder decision-making

The emergence and evolution of GLP-1 receptor agonists have reshaped therapeutic approaches across metabolic and cardiovascular disciplines, prompting rapid innovation in drug development, formulations, and delivery. These agents, defined by their incretin-mimetic mechanisms, have pushed clinical conversations beyond glycemic control to broader endpoints such as weight management and cardiovascular risk modulation. As a result, stakeholders across clinical, payer, and commercial domains confront a more complex decision environment where therapeutic value, patient access, and long-term outcomes intersect.

In this context, a rigorous executive summary seeks to synthesize cross-functional intelligence into actionable conclusions. It is essential to contextualize product-level advances alongside regulatory trends, manufacturing scalability, and evolving distribution pathways. Transitioning from trial results to routine practice requires alignment across clinical guidelines, reimbursement frameworks, and patient adherence strategies, and therefore this introductory overview foregrounds those interdependencies while setting the stage for deeper analysis. By framing the subsequent sections around transformative shifts, tariff-related supply dynamics, segmentation intelligence, regional perspectives, competitive positioning, and pragmatic recommendations, readers are equipped to move from insight to implementation with clarity and purpose.

A detailed examination of the major structural and clinical shifts transforming product development, patient care pathways, and commercial strategies for GLP-1 therapies

The landscape for GLP-1 receptor agonists has undergone several transformative shifts that warrant attention from industry leaders and clinicians alike. First, therapeutic indications have broadened: these agents are now evaluated and adopted not only for glycemic control but also for weight reduction and cardiometabolic risk mitigation, which has altered clinical pathways and prescribing considerations. Concurrently, formulation science has accelerated, creating a divergence between long-acting and short-acting profiles and enabling new administration paradigms that influence adherence and patient preference.

Second, competition and innovation have intensified, driven by both incumbent pharmaceutical companies optimizing existing molecules and newcomers advancing differentiated modalities, including oral peptides and combination dual agonists. This competitive pressure has catalyzed strategic behavior such as label expansions, lifecycle management, and collaborations to secure manufacturing capacity and distribution reach. Third, payer and health systems are re-evaluating value frameworks to balance up-front therapeutic costs with downstream benefits in comorbidity reduction and health resource utilization, prompting more nuanced outcomes-based contracting and utilization management approaches.

Finally, patient expectations and care models are shifting toward integrated chronic disease management with digital health support, remote monitoring, and coordinated care teams. These changes amplify the importance of patient education, adherence support, and real-world evidence generation. Taken together, these shifts are not isolated; they interlink regulatory strategy, clinical adoption, commercial execution, and supply chain planning, demanding an integrated response from stakeholders across the ecosystem.

An analysis of how United States tariff measures introduced in 2025 compound supply chain complexity, sourcing decisions, and commercial continuity for GLP-1 therapies

Tariff policy and trade measures implemented by the United States in 2025 introduce a material layer of complexity to GLP-1 supply chains, affecting sourcing decisions, cost structures, and strategic planning. While active pharmaceutical ingredients and certain formulation inputs are globally dispersed, tariffs can increase landed input costs and incentivize sourcing pivots or geographies with tariff advantages. In response, companies are reassessing supplier footprints, evaluating near-shore manufacturing expansions, and accelerating bilateral supply agreements to limit exposure to import duties and logistics volatility.

Moreover, the cumulative impact of tariff-driven cost pressures interacts with already tight manufacturing capacity for biologics and peptide therapeutics. Manufacturers may prioritize production allocation based on commercial strategy and contractual obligations, which could affect product availability windows and inventory planning across distribution channels. Payers and providers may experience resultant shifts in procurement timing and cost recovery strategies, and pharmaceutical companies may pursue differential pricing algorithms or value-based arrangements to preserve access while managing margin compression.

Importantly, regulatory conformity and quality assurance remain non-negotiable constraints; relocation of manufacturing or requalification of suppliers requires time and regulatory engagement. Consequently, a proactive approach that blends procurement diversification, strategic inventory buffers, and close dialogue with regulatory authorities can mitigate tariff-induced disruption. Companies that model tariff scenarios within supply planning and that invest early in alternative sourcing or capacity will be better positioned to sustain continuity of supply and to preserve clinical and commercial momentum.

Key segmentation-driven insights revealing how drug class, formulation type, administration route, therapeutic application, and distribution channels determine strategic priorities

Segmentation insights reveal differentiated dynamics across drug class, drug type, route of administration, clinical application, and distribution pathways that shape product positioning and lifecycle priorities. Within drug class, established molecules such as Dulaglutide, Liraglutide, and Semaglutide exhibit distinct clinical profiles and evidence bases that inform guideline integration and prescriber preference, which in turn affect messaging and medical affairs strategies. At the drug type level, contrasting long-acting agonists versus short-acting agonists create divergent adherence patterns, dosing convenience considerations, and portfolio trade-offs, prompting firms to align formulation investments with targeted patient populations and care settings.

Route of administration remains a pivotal differentiator: oral versus parenteral options alter adoption curves, patient acceptance, and pharmacy workflow; oral formulations can expand reach into primary care, whereas parenteral deliveries often require structured clinical touchpoints and training. Application segmentation spanning cardiovascular health, diabetes management, and weight management generates overlapping yet distinct evidence requirements; cardiovascular indications emphasize long-term outcomes and event reduction, diabetes management centers on glycemic metrics and safety, and weight management prioritizes durable weight loss and quality-of-life endpoints. Therefore, clinical development plans and evidence generation must be tailored to each application to satisfy distinct stakeholders.

Finally, distribution channel nuances-hospital pharmacies, online pharmacies, and retail pharmacies-demand differentiated commercial models. Hospital pharmacies typically engage in formulary negotiation and inpatient or specialty clinic distribution, online pharmacies emphasize convenience and direct-to-patient channels with adherence support, and retail pharmacies serve broad outpatient dispensing with opportunities for point-of-care education. Integrating channel-specific logistics, patient support programs, and digital engagement strategies will be central to maximizing treatment persistence and aligning commercial execution with clinical value propositions.

Regional intelligence synthesizing regulatory, payer, and infrastructure differences across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape adoption trajectories

Regional dynamics for GLP-1 receptor agonists are shaped by regulatory environments, payer architectures, and healthcare delivery models across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct adoption pathways and operational considerations. In the Americas, adoption has been accelerated by strong clinical advocacy and rapid guideline integration for cardiometabolic indications, yet reimbursement frameworks and heterogeneity in payer policies require targeted value demonstrations and outcomes data to secure broad access. Consequently, commercial strategies emphasize real-world evidence and payer engagement to translate clinical benefit into covered therapies.

Within Europe, Middle East & Africa, regulatory harmonization in some jurisdictions is counterbalanced by fragmented reimbursement landscapes and variable infrastructure for chronic disease management, requiring adaptive launch sequencing and local evidence generation. Stakeholders often prioritize health economic modeling and regional outcome studies to inform national and subnational reimbursement decisions. Meanwhile, in the Asia-Pacific region, diverse regulatory pathways and rapidly evolving healthcare investment create both challenges and opportunities; some countries show fast uptake driven by public health priorities around diabetes and obesity, while others face constraints from limited specialist capacity and different affordability thresholds.

Across these regions, supply chain resilience, cold-chain management for parenteral products, and local manufacturing capabilities factor heavily into execution. Strategic regional planning that aligns clinical development timelines, regulatory submissions, and payer engagement with local infrastructure realities will be critical for optimizing launch sequencing and ensuring sustained patient access across heterogeneous health systems.

An integrated view of competitive positioning, strategic alliances, and manufacturing and regulatory execution priorities that define company-level success in GLP-1 therapeutics

Competitive and corporate dynamics in the GLP-1 domain reflect a combination of established pharmaceutical leadership, targeted lifecycle optimization, and an expanding ecosystem of service providers focused on capacity and delivery innovation. Leading originator companies maintain deep clinical trial programs and broad regulatory experience, deploying strategies that include indication expansion, differentiated dosing regimens, and investment in oral and alternate delivery platforms. These initiatives are supported by substantial R&D operations and global regulatory footprints, enabling sophisticated evidence generation and guideline influence.

Alongside large pharmaceutical sponsors, specialized contract manufacturers, formulation developers, and technology partners play a critical role in scaling peptide production and developing stability and oral bioavailability solutions. Strategic alliances and capacity-sharing agreements have become common as companies seek to de-risk supply and accelerate time to clinic while preserving quality. Mergers, licensing deals, and targeted in-licensing of novel candidates are frequently used to fill pipeline gaps or to secure complementary mechanisms of action.

Operational excellence in manufacturing, regulatory agility, and the ability to deliver robust post-launch support programs have emerged as differentiators. Firms that coordinate regulatory strategy with manufacturing scale-up and who invest in post-marketing evidence generation can better support payer negotiations and provider adoption. Moreover, companies that couple clinical credibility with patient-centric services-such as adherence tools and integrated care pathways-are positioned to capture sustained utilization and to reinforce therapeutic value in real-world settings.

Actionable recommendations for industry leaders focused on evidence alignment, supply chain resilience, channel-specific commercialization, and outcome-based contracting to protect pipeline value

Industry leaders should adopt a set of pragmatic, actionable initiatives to navigate commercialization complexities and to protect pipeline value as GLP-1 therapies proliferate. First, align clinical development and evidence generation with payer and guideline requirements early, prioritizing outcomes that matter to payers, clinicians, and patients. This alignment reduces time to reimbursement decisions and supports broader adoption when therapies demonstrate compelling real-world benefits beyond surrogate endpoints.

Second, reinforce supply chain resilience by diversifying suppliers, evaluating near-shore manufacturing capacity, and integrating tariff scenario planning into procurement. Anticipatory investment in alternative sourcing reduces the risk of disruption and preserves launch and replenishment timelines. Third, design distribution and patient support models that reflect channel differences; invest in digital adherence tools for direct-to-patient channels, while ensuring hospital and retail pathways receive tailored educational and logistical support. Fourth, pursue strategic partnerships for formulation innovation, enabling oral or less frequent dosing options that expand addressable patient populations and improve adherence.

Finally, implement outcome-based contracting and risk-sharing arrangements selectively, using robust real-world data collection to demonstrate longitudinal benefits. These agreements can bridge payer concerns about upfront costs while aligning commercial incentives with sustained clinical outcomes. By combining these initiatives with disciplined portfolio prioritization and operational readiness, organizations can maximize therapeutic impact and sustain competitive advantage in a rapidly evolving landscape.

A transparent and rigorous research methodology combining primary stakeholder interviews, regulatory and clinical literature analysis, and scenario validation for actionable intelligence

The research methodology underpinning this executive synthesis integrates multiple qualitative and quantitative approaches to ensure robust, triangulated insights. Primary research included structured interviews with clinicians, payers, procurement specialists, and commercial leaders to capture decision drivers across clinical adoption, reimbursement negotiation, and distribution execution. These stakeholder discussions were complemented by systematic reviews of regulatory guidance, clinical trial registries, and peer-reviewed literature to map indication-specific evidence needs and safety profiles.

Secondary analyses synthesized publicly available regulatory filings, product labels, and pharmacovigilance disclosures to understand comparative safety and dosing paradigms. Supply chain and manufacturing assessments leveraged capacity mapping and supplier profiling to evaluate risk exposure and options for near-term scale adjustments. Throughout, findings were validated through cross-checks with industry experts and by scenario testing to assess sensitivity to policy shifts, such as tariff changes and regulatory timelines.

Data synthesis emphasized evidence quality, reproducibility, and the practical implications of findings for clinical strategy, manufacturing planning, and commercial execution. By combining stakeholder input, documentary analysis, and scenario modeling, the methodology delivers actionable intelligence that is both empirically grounded and strategically oriented toward decision-making needs.

A conclusive synthesis emphasizing the need for integrated, evidence-driven strategies across development, supply, and commercialization to realize therapeutic potential

In conclusion, GLP-1 receptor agonists represent a class of therapeutics that has rapidly expanded beyond traditional glycemic management into broader cardiometabolic care, driving new clinical paradigms and commercial imperatives. The interplay of formulation innovation, competitive dynamics, and evolving payer expectations requires an integrated response across clinical development, regulatory engagement, supply chain strategy, and channel-specific commercialization. Stakeholders who proactively align evidence generation with payer needs, diversify supply pathways in anticipation of trade policy shifts, and invest in patient support and outcome tracking will be better positioned to translate clinical promise into sustainable therapeutic impact.

As adoption pathways diversify across regions and channels, tailored strategies that respect local regulatory and reimbursement realities while leveraging global clinical data will be essential. Ultimately, success will hinge on the ability to synchronize scientific differentiation with operational readiness and stakeholder alignment so that patient access, clinical outcomes, and commercial viability advance in tandem. The insights summarized here provide a strategic foundation to inform those decisions and to prioritize next steps across development, manufacturing, and market access functions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. GLP-1 Receptor Agonist Market, by Drug Class

  • 8.1. Dulaglutide
  • 8.2. Liraglutide
  • 8.3. Semaglutide

9. GLP-1 Receptor Agonist Market, by Drug Type

  • 9.1. Long-Acting Agonists
  • 9.2. Short-Acting Agonists

10. GLP-1 Receptor Agonist Market, by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. GLP-1 Receptor Agonist Market, by Application

  • 11.1. Cardiovascular Health
  • 11.2. Diabetes Management
  • 11.3. Weight Management

12. GLP-1 Receptor Agonist Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. GLP-1 Receptor Agonist Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. GLP-1 Receptor Agonist Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. GLP-1 Receptor Agonist Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States GLP-1 Receptor Agonist Market

17. China GLP-1 Receptor Agonist Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amgen Inc.
  • 18.6. AstraZeneca Inc.
  • 18.7. Bachem Group
  • 18.8. Biopharma PEG
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. Calibrate Health, Inc.
  • 18.11. Cleveland Clinic
  • 18.12. Daiichi Sankyo Company, Limited
  • 18.13. Diabetes UK
  • 18.14. Eli Lilly and Company
  • 18.15. GenScript
  • 18.16. GlaxoSmithKline plc
  • 18.17. GoodRx, Inc.
  • 18.18. Hanmi Pharm.Co.,Ltd.
  • 18.19. Innovent Biologics, Inc.
  • 18.20. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 18.21. Merck & Co., Inc.
  • 18.22. Novo Nordisk A/S
  • 18.23. Oramed Pharmaceuticals Inc.
  • 18.24. Patsnap (UK) Ltd.
  • 18.25. Pfizer Inc
  • 18.26. Sanofi SA
  • 18.27. Sun Pharmaceutical Industries Ltd.
  • 18.28. Twist Bioscience Corporation
  • 18.29. WebMD LLC.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GLP-1 RECEPTOR AGONIST MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LONG-ACTING AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LONG-ACTING AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LONG-ACTING AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SHORT-ACTING AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SHORT-ACTING AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SHORT-ACTING AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY WEIGHT MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY WEIGHT MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GCC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. G7 GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. NATO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)